Sarcopenia: burden and challenges for public health by Charlotte Beaudart et al.
ARCHIVES OF PUBLIC HEALTH
Beaudart et al. Archives of Public Health 2014, 72:45
http://www.archpublichealth.com/content/72/1/45COMMENTARY Open AccessSarcopenia: burden and challenges for public
health
Charlotte Beaudart1,2*, René Rizzoli3, Olivier Bruyère1,2,5, Jean-Yves Reginster1,4 and Emmanuel Biver3Abstract
Sarcopenia, operationally defined as the loss of muscle mass and muscle function, is a major health condition associated
with ageing, and contributes to many components of public health at both the patient and the societal
levels. Currently, no consensual definition of sarcopenia exists and therefore it is still a challenge to establish
the actual prevalence of sarcopenia or to establish the direct and indirect impacts of sarcopenia on public
health. Anyway, this geriatric syndrome represents a huge potential public health issue because of its multiple
clinical and societal consequences. Moreover, all these aspects have an impact on healthcare costs both for
the patient and the society. Therefore, the implementation of effective and broadly applicable preventive and
therapeutic interventions has become a medical and societal challenge for the growing number of older
persons affected by sarcopenia and its disabling complications.
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Thanks to social, health and technological progress, the
proportion of older people in the age pyramid is increas-
ing all over the world. According to the World Health
Organisation, in 2050 there should be at least 2 milliards
of people aged 65 years or older, compared to 600 million
today. The life expectancy is also increasing and is esti-
mated around 80 years in industrial countries [1]. The
aging process is responsible of many changes in body
composition including a loss of skeletal muscle mass.
From the age of 25, there is a progressive decrease in the
size and number of muscle fibres resulting in a loss of
about 30% of muscle mass at the age of 80 [2]. Beyond
some defined threshold, this age-related loss of muscle
mass is characterized as abnormal. To characterize this
phenomenon, the term “sarcopenia” was firstly introduced
by Irwin Rosenberg [3]. The definition of sarcopenia was
then enriched with scientific and technological advances
and gradually evolved to incorporate the notions of de-
creased muscle mass [4], then of decreased muscle func-
tion (low muscle strength or low physical performance)* Correspondence: c.beaudart@ulg.ac.be
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unless otherwise stated.[5-11]. These definitions differ from each other in regards
to muscle mass indicators (ratio of appendicular lean mass
over height squared, ALM/ht2, or over body mass index,
ALMBMI), the cutpoints for slow gait speed and whether
or not they include a measure of weakness (Table 1).
However, there is actually no universal consensus for an
operational definition of sarcopenia, which is an important
issue for public health.
A wide range of techniques can be used to measure
the different components of sarcopenia [12]. Three tech-
niques can be used for the measurement of appendicular
lean mass: body imaging techniques, bio impedance ana-
lysis and anthropometry measures. In research, the two
gold standards are the computed tomography (CT-scan)
and the magnetic resonance imaging (MRI). However,
because of the high costs and the limited access to this
kind of equipment, the European Working Group on
Sarcopenia in Older People (EWGSOP) [8] recommends
in clinical practice, first the use of either dual energy X-
ray absorptiometry (DXA) or, as a portable alternative to
DXA, the bioelectrical impedance analysis (BIA). Despite
their easy use in clinical practice, the anthropometric
measures are not recommended for the diagnosis of sar-
copenia because these measures are not validated in
older people and are, therefore, vulnerable to error. Sev-
eral techniques are also available for the measurement ofal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Proposed operational definitions of sarcopenia
Criteria Muscle mass Muscle function
Muscle strength Physical performance
Baumgartner criteria [4] Sarcopenia ASM/ ht2 > 2 SD below young healthy mean x x
European Society for Clinical Nutrition and
Metabolism Special Interest Groups (ESPEN-SIG) [7]
Sarcopenia Percentage of muscle mass ≥2 SD below mean in
young adults of the same sex and ethnic background
(individuals aged 18–39 years in the NHANES III cohort)
x Gait speed: <0.8 m/s or Reduced
performance in any functional test
used for comprehensive geriatric
assessment
European Working Group on Sarcopenia in Older
People (EWGSOP) [8]
Sarcopenia ALM/ht2 Grip strength OR Gait speed: <0.8 m/s
- Men: ≤7.23 kg/m2 - Men: <30 kg
- Women: ≤5.67 kg/m2 - Women: <20 kgSevere
sarcopenia
AND
International Working Group on Sarcopenia
(IWGS) [9]
Sarcopenia ALM/ht2 x Gait speed: <1.0 m/s
- Men: ≤7.23 kg/m2
- Women: ≤5.67 kg/m2




ALM/ht2 > of 2 SD below the mean of healthy persons
aged 20–30 years of the same ethnic group
x Gait speed: ≤1.0 m/s or Walking
distance < 400 m during a 6-min walk
Foundation of NIH Sarcopenia Project [11] Weakness and
low lean mass
ALMBMI Grip strength x
- Men: <0.789 - Men: <26 kg
- Women: <0.512 - Women: <16 kgSlowness with
weakness and
low lean mass
AND Gait speed: ≤0.8 m/s
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used for the diagnosis of sarcopenia: handgrip strength,
knee flexion or knee extension strength and the measure-
ment of peak expiratory flow. In clinical research, the
handgrip strength is the most widespread method. Indeed,
this method does not require any special equipment, has
been documented as a good marker of physical perform-
ance among community-dwelling older people and is well
correlated with leg strength [13,14]. Finally, the physical
performance can be measured by the “short physical per-
formance battery test (SPPB)”, by the “usual gait speed” or
by the “timed up and go test” or “stair climb power test”.
The EWGSOP [8] recommends the use of either the usual
gait speed, measured on a 4-meter distance or the SPPB
test [15] which is a composite measuring walk speed,
balance and the ability to stand up 5 times from a chair.
Different cut-offs have been developed by the EWGSOP
for each variable and could be applied for the diagnosis of
sarcopenia. Recently, the Foundation of NIH Sarcopenia
Project proposed recommendations for cut-off points
for weakness and low lean mass definitions aiming to
provide an operational definition for sarcopenia. It was
recommended to assess muscle strength by grip strength
with cutpoints <26 kg in men and <16 kg in women,
and low lean mass by appendicular lean mass ad-
justed to BMI, with respective cutpoints <0.789 kg/m2
and <0.512 kg/m2 [16].
Given the variability in the definitions of sarcopenia, it
is still a challenge to establish the actual prevalence of
sarcopenia according to age and gender and to assess
the direct and indirect impacts of sarcopenia on public
health. The aim of this review is to discuss, both broadly
and specifically, the public health implication of sarcope-
nia and its association with objectives health-related out-




Sarcopenia is very common in older people. Currently it
is still a public health challenge to establish a prevalence
of sarcopenia. Indeed, this estimated prevalence depends
on the type of studied population. A large number of
studies have assessed the prevalence of sarcopenia within
a cohort of adult subjects and this estimated prevalence
could range from 0.1% to 85.4% according to patients’
characteristics [17-22]. Globally, a higher prevalence of
sarcopenia is often observed in men, in elderly subjects,
in subjects living in nursing home, in subjects having a
low body mass index but also in subjects having a low
educational level. The prevalence of sarcopenia seems
also to differ according to ethnicity. Indeed, a higher
prevalence of sarcopenia is observed in Asian people
and a lower prevalence is observed in people with darkskin compared to Caucasian people. Recently, a systematic
review [23] on the prevalence of sarcopenia has been pub-
lished. It indicates that the prevalence of EWGSOP-defined
sarcopenia is 1-29% for older adults living in community.
The differences in prevalence seem attributable to the age
of the population and the methods of assessment used but
also to the cut-offs used for the diagnosis.
Prevalence of sarcopenia could also differ depending
on the definitions used for the diagnosis of sarcopenia,
as recently highlighted in the comparison of the FNIH
criteria with the International Working Group and the
European Working Group for Sarcopenia in Older Persons
[11]. In 2013, Batsis et al. [24] compared eight definitions
of sarcopenia and found a prevalence ranging from 4.4%
to 94% across definitions. In 2013, Bijlsma et al. found that
the prevalence of sarcopenia with different diagnostic cri-
teria ranged from 0% to 20.8% in the lowest age category
(below 60 years), from 0% to 31.2% in the middle (60 to
69 years) and from 0% to 45.2% in the highest (above
70 years) [25]. As expected, studies using muscle mass as
single criterion of diagnosis revealed a higher prevalence
of sarcopenia than studies based on the EWGSOP consen-
sus algorithm. The choice of cut-off limits applied could also
influence the prevalence of sarcopenia. This is confirmed in
a study (performed in our Department, in press) showing
that the prevalence of sarcopenia can vary from 9.25% to
18% depending on the cut-offs used. This same study also
shows the importance of the diagnostic tool chosen for the
measurement of muscle mass, muscle strength and physical
performance. Depending on the tool used, the prevalence
of sarcopenia can range from 8.4% to 27.6%.
Sarcopenia is also often related to multiple pathologies
and comorbidities which can also compromise the meas-
urement of its prevalence. Some authors are actually inter-
ested in sarcopenia in combination with another health
issue, like osteoporosis, osteopenia, obesity, type II diabetes
mellitus, breast cancer, etc. The prevalence of sarcopenia is
systematically higher in subjects presenting another health
condition than in healthy subjects. Sarcopenia could be, in
this case, considered as one consequence of this health
problem.
This confused state and the current impossibility of estab-
lishing a clear prevalence of sarcopenia makes comparisons
between studies difficult and thus represents an important
public health issue. Moreover, the various values for the
prevalence of sarcopenia found across studies are probably
associated with different characteristics of sarcopenic sub-
jects which could compromise the implementation of per-
tinent therapeutic strategies in the field of sarcopenia.
Consequences of sarcopenia: Indirect impact on public
health
Many consequences of sarcopenia are prognostic indica-
tors of public health burden, such as the development of
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hospitalization, and even mortality [26]. In particular,
sarcopenia is associated with poor physical performance,
functional decline and physical disability [22,26]. Sarco-
penia predicts loss of independence for daily life activ-
ities in elderly men and women [27,28], and also affects
gait speed or regularity. Leg lean mass has been identi-
fied as an independent predictor of the level of mobility
impairment assessed by the SPPB test [29]. Ability to
walk is an obvious determinant of subsequent disability,
mortality, and health care costs [30]. Sarcopenia is also
associated with falls, a well known issue regarding the
risk of fracture and disabilities (odds ratio for fall in the
sarcopenia group relative to the normal group: 4.42
(95% CI 2.08-9.39) in men and 2.34 (95% CI 1.39-3.94)
in women) [31].
Sarcopenia is also associated with many comorbidities
which have a major impact on public health. As occur-
ring concomitantly with age-related bone loss, sarcope-
nia coexists with osteoporosis and may increase fracture
risk, potentially directly via crosstalk between muscle
and bone tissues [32,33] and indirectly via increase of
risk of falling [34,35]. Most of endocrine diseases (diabetes,
hypogonadism, hypercortisolism…) as well as obesity, or
chronic kidney disease [34], are associated with sarcopenia
independently of age-related muscle loss, which may be an
underlying mechanism by which chronic diseases cause
physical disability [36].
In this context, sarcopenia is also associated with greater
risk of hospitalization [37] and is highly prevalent among
older adults admitted to acute care wards [38] or in nurs-
ing homes [39]. Sarcopenia is also a predictor of bad out-
comes in patients who undergo major general or vascular
surgery [40] or with serious illness, such as in transplant-
ation or cancer outcome [41,42]. All these health-related
consequences of sarcopenia are supposed to alter quality
of life in these patients [43].
Importantly, several studies indicate that sarcopenia
and indicators of alterations of muscle strength (such as
grip strength, walking speed, chair rises, or standing bal-
ance) predict future mortality in middle-aged and older
adults [21,44]. Sarcopenia is also associated with short-
and long-term mortality in hospitalized patients [38], or
in nursing home elderly residents [45].
Taken together, these data highlight how sarcopenia
may impact various public health components, at the pa-
tient level with higher rate of disabilities, loss of independ-
ence, bad comorbidities outcome, institutionalization or
mortality, but also at the societal level, contributing
to major healthcare and dependence costs in disabled sar-
copenic elderly (Figure 1). However, none of the proposed
operational definitions of sarcopenia demonstrated its
superiority to be predictive of these health-related “hard”
outcomes, such as fractures, falls, admission in nursinghomes, or mortality. Future researches are clearly needed
in this field to clarify which operational definition of
sarcopenia should be integrated in clinical practice to
diagnose and target sarcopenia and its impact on public
health.
Public health costs of sarcopenia
Disability is associated with an increased risk of hospitalization
and nursing home placement, increased home healthcare
and, obviously, health care expenditure. Given the effect
of sarcopenia on disability, public health costs of sarcope-
nia are expected to be high. Currently, economic data on
sarcopenia are very poor. Only one study has currently re-
ported the healthcare costs of sarcopenia in the United
States [46]. Those estimates have taken into consideration
the direct costs of sarcopenia which raised, in 2000, to
$18.5 billion, $10.8 billion in men and $7.7 billion in
women. These costs are represented by hospitalization,
nursing home admissions and home healthcare expend-
iture. In 2000, this amount represented about 1.5% of
total health expenditure in the United States. It must
be added that, in addition to disability, sarcopenia is
associated with multiple comorbidities and may also
have effect on osteoporosis [47], obesity [48] and type
II diabetes mellitus [49]. Whith these comorbidities
associated healthcare costs taken into account, the
economic burden of sarcopenia may probably be even
more important than reported in the study of Janssen
[46]. This study is currently unique and, until now, no re-
liable economic assessment of sarcopenia has been per-
formed in Europe.
Despite this lack of other economical assessment, sev-
eral studies have however looked at the relationship be-
tween sarcopenia and different area of expenditure such
as hospitalization or nursing home admission. In the
United kingdom, one study has shown that, in comparison
with patients without sarcopenia, those diagnosed with
sarcopenia presented a mean length stay in hospital sig-
nificantly higher (mean of 13.4 ± 8.8 days for sarcopenic
subjects versus 9.4 ± 7 days for non-sarcopenic subjects;
p = 0.003) [50]. The association between sarcopenia and
hospitalization was examined in another study [37] show-
ing a significant association between low muscle density
(RR 1.5, 95% CI 1.2-1.7) and grip strength (RR 1.5, 95% CI
1.3-1.8) with hospitalization. Lean mass was however not
associated with risk of hospitalization.
Although some studies have shown a higher risk of
institutionalization among frail people [51-53], regarding
sarcopenia specifically, no study has currently assessed
the relationship between sarcopenia and nursing home
admissions [54].
Sarcopenia is also associated with other healthcare
costs area such as loss of productivity, reduced quality of
live and loss of autonomy but also with psychological
Figure 1 The complex burden of sarcopenia on public health.
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never been quantified, neither in the US, nor in Europe.
In their assessment of healthcare costs of sarcopenia in
the United States, Janssen et al. [46] also examined the ef-
fect that reduced prevalence of sarcopenia would have on
healthcare expenditure, through for example pharmaco-
logical treatment, public health campaigns, physical activ-
ity intervention,. They found that a 10% reduction in the
prevalence of sarcopenia would result in saving $1.1 per
year in the US. In a public health context, this potential
economic saving is important. In comparison with osteo-
porotic fractures, for which the economic costs are similar
[55] and for which numerous public health campaigns are
organized aiming at reducing their occurrence, it is start-
ling to note that, for sarcopenia, no public health cam-
paigns are directly aimed at reducing the prevalence of
this important geriatric syndrome. Because the number of
older people is increasing all over the world, health policy
decision-makers should consider some money investment
in sarcopenia prevention and treatment to ensure import-
ant future savings.Targeting sarcopenia: potential impact on public health
Obviously there is currently no consensual operational
definition of sarcopenia. This age-related condition has
numerous consequences in public health, illustrated with
relevant hard clinical outcomes such as falls, fractures,
hospitalisations, institutionalizations, mortality. These
consequences directly induce high personal, social and
health care systems costs, which will most certainly in-
crease steadily with population ageing. The implementation
of effective and broadly applicable preventive interventions
has become a medical and societal challenge for the grow-
ing number of older persons affected by sarcopenia and its
disabling complications. Identifying and targeting the de-
terminants of sarcopenia is a necessary first step to limit
its impact on public health (Figure 1). In addition to the
identification of the determinants of skeletal muscle loss,
research strategies will have to include a lifecourse ap-
proach focused on factors associated with peak muscle
mass and strength, such as birth weight [56] and early nu-
trition [57]. Nutritional interventions may influence sarco-
penia, in particular diets rich in proteins and antioxidant
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plements. Various exercise-related interventions (resistance
exercise training, gait, balance, coordination and func-
tional exercises) have been tested, targeting muscle
strength, physical function, the risk of falls and balance
in older people [58]. Potent pharmaceutical therapies have
been proposed, such as hormone therapies (growth hor-
mone, testosterone, selective androgen receptor modulator
dehydroepiandrosterone, estrogen), angiotensin converting
enzyme inhibitors, ghrelin agonists, but with up to now,
little convincing effects or with presenting adverse side
effects [58]. One of the most promising approaches may
be the inhibition of myostatin, a regulator of muscle develop-
ment and growth [59,60]. It is likely that combining lifestyle,
nutritional, pharmacological and physical interventions is
the most promising strategy. Clinical trials are currently
conducted in this direction, such as the DoHealth study,
which combines vitamin D, omega-3 fatty acids and
physical exercise for the prevention of diseases at older age
(ClinicalTrials.gov Identifier: NCT01745263). The cost-
benefit ratio of these interventions will have to be assessed
in health economic models based on health care utilization
and incidence of chronic diseases. However, a gap persists
regarding assessment of specific health conditions related
to sarcopenia, as fracture has become the relevant out-
come to evaluate interventions targeting osteoporosis. Val-
idation of specific, objective and reproducible outcomes or
tools is a necessary step before considering the develop-
ment of interventions targeting sarcopenia and likely to be
recognized both by the scientific and medical community
and regulatory agencies.
Conclusion
Sarcopenia has become a major health condition associ-
ated with ageing, and contributes to many components
of public health at both the patient and the societal
levels. It interferes with the incidence and prognosis of
many comorbidities, and obviously increases health care
utilization. It is a determinant of loss of independence,
leading to institutionalizations or prolonged hospitaliza-
tions. All these aspects increase healthcare costs for the
society, and affect quality of life and mortality of sarco-
penic patients. With the improvement of life expectancy
and the consensual previsions of marked increase of the
proportion of older people, it is urgent to consider the
economic and societal burden of sarcopenia, and to im-
plement interventions to prevent and treat sarcopenia in
the ageing population.Abbreviations
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